Opus Genetics (IRD) Capital Expenditures (2010 - 2019)

Opus Genetics (IRD) has 9 years of Capital Expenditures data on file, last reported at $5617.0 in Q4 2019.

• Capital Expenditures for Q4 2019 came in at $5617.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $25000.0 (down 36.26% YoY), and the FY2019 annual result was $25000.0, down 36.26% from the prior year.
• Capital Expenditures slipped to $5617.0 in Q4 2019 per IRD's latest filing, from $6202.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $53799.0 in Q4 2017 and troughed at $403.0 in Q4 2016.
• A 5-year average of $11686.7 and a median of $5106.5 in 2016 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2016 and 2017: Capital Expenditures plunged 98.13% in 2016, then surged 13249.63% in 2017.
• A 5-year view of Capital Expenditures shows it stood at $9803.0 in 2015, then sank by 95.89% to $403.0 in 2016, then surged by 13249.63% to $53799.0 in 2017, then sank by 33.58% to $35731.0 in 2018, then plunged by 84.28% to $5617.0 in 2019.
• Business Quant data shows IRD's Capital Expenditures at $5617.0 in Q4 2019, $6202.0 in Q2 2019, and $13181.0 in Q1 2019.